Scandinavian Biopharma välkomnar Dilek Merdol som ny chef för Quality Control (QC)
Scandinavian Biopharma fortsätter att expandera och har nu rekryterat Dilek Merdol som ny QC chef.
Ämnen: Medicin, läkemedel
-
-
Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin
In record time we completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to West Africa. In total 743 travellers spent a fortnight in Benin. Half of the group were given the ETEC vaccine candidate, ETVAX®, and the other half placebo. The aim of the study was to evaluate safety and estimate the protective efficacy in a naive population.
-
Scandinavian Biopharma har slutfört rekrytering av resenärer till bolagets fas IIB-studie i Benin
På rekordtid slutförde vi en randomiserad, dubbelblind, placebokontrollerad fas IIB-studie i finländska resenärer till Västafrika. De sista resenärerna lämnade Benin i mars 2019. Totalt har 743 resenärer spenderat två veckor i Benin. Syftet med studien var att utvärdera vaccinets säkerhet och uppskatta den kliniska skyddseffekten i resenärer.
-
Scandinavian Biopharmas prövningsprogram i Afrika invigdes av Hälsoministeriet i Zambia tillsammans med den Svenska Ambassadören
I går, onsdagen den 17 april, invigdes Scandinavian Biopharmas kliniska prövningsprogram i Afrika för bolagets vaccinkandidat ETVAX®. The Permanent Secretary at Ministry of Health, Dr Kenndy Malama invigde tillsammans med Henrik Cederin, Sveriges Ambassadör i Zambia, Dr Izukanji Sikazwe, CEO vid Center for Infectious Disease Research i Zambia (CIDRZ) och Dr Godfrey Biemba, CEO på National Health R
-
Scandinavian Biopharma officially starts their late phase development program in Africa funded by EDCTP
This trial will establish the exact safe and immunogenic dose of the vaccine in young children (6-23 months of age) as well as to explore the potential benefits of a third booster dose. The study will be initiated in healthy adults and followed by young children (6-23 months of age) in Zambia starting from May 2019.
-
Scandinavian Biopharma recruits Madelene Franzén as Accounting Manager
Scandinavian Biopharma continues to expand and now welcomes Madelene Franzén as Accounting Manager. Madelene has previously been an authorized accounting consultant and will be responsible for Scandinavian Biopharma's accounts.
-
Scandinavian Biopharma rekryterar Madelene Franzén som Accounting Manager
Scandinavian Biopharma fortsätter att expandera och välkomnar nu Madelene Franzén som Accounting Manager. Madelene har tidigare varit auktoriserad redovisningskonsult och kommer att ansvara för Scandinavian Biopharmas redovisning.
-
Scandinavian Biopharma has been awarded 7.4 million EUR from the EU for clinical trials of ETVAX® – a unique and newly developed vaccine against diarrheal disease
In international competition Scandinavian Biopharma has been awarded a grant of 7,4 million Euro for clinical trials of the ETEC vaccine ETVAX®. The trials will be conducted in Zambia and The Gambia. The newly developed vaccine ETVAX® targets diarrhea caused by ETEC – an enteric bacteria responsible for hundred thousands of deaths annually among children in low- to middle income countries.
-
Scandinavian Biopharma har beviljats 7,4 miljoner Euro från EU för kliniska prövningar av ETVAX® – ett nytt och unikt diarrévaccin
Scandinavian Biopharma har i tuff internationell konkurrens beviljats ett anslag på 7,4 miljoner Euro för kliniska prövningar av ETEC-vaccinet ETVAX®. Prövningarna kommer genomföras i Zambia och Gambia. ETVAX® är ett nyutvecklat vaccin som avser skydda mot diarré orsakad av ETEC – en bakterie som orsakar hundratusentals dödsfall per år hos barn i låg- och medelinkomstländer.
-
Tomas Åslund joins Scandinavian Biopharma as VP Manufacturing
Scandinavian Biopharma continues to expand and strengthen its organization. Tomas Åslund has now started as VP Manufacturing at Scandinavian Biopharma. Tomas has more than 30 years’ experience from the pharmaceutical and life science industry within the field of recombinant protein drugs.
-
Tomas Åslund till Scandinavian Biopharma som VP Manufacturing
Scandinavian Biopharma fortsätter att expandera och stärka sin organisation och välkomnar nu Tomas Åslund som VP Manufacturing. Tomas har mer än 30 års erfarenhet från läkemedels- och Life Science industrin, främst inom området rekombinanta proteiner.
-
Vi är ”Årets företagare i Solna 2018”
I konkurrens med 10 000 andra företag blev vi på Scandinavian Biopharma idag korade som "Årets företagare i Solna.
-
Världens största pris inom området global hälsa har tilldelats vår samarbetspartner, Jan Holmgren
Professor Jan Holmgren is one of this year’s recipients of Prince Mahidol’s Award in Public Health - the world’s biggest award in the field of global health. Jan is receiving the award for his ground-breaking research on the development of the world’s first effective drinkable cholera vaccine and for showing that cholera vaccine has the potential to eradicate cholera in developing countries.
-
Scandinavian Biopharma vann upphandlingen med diTekiBooster, igen!
The national public tender for the booster of TdaP vaccine (diphtheria, tetanus and pertussis), has now been completed. Scandinavian Biopharma was for the second consecutive period awarded this tender and diTekiBooster will continue to be administered to all adolescents in Sweden 13-14 years old. diTekiBooster was considered to have a medical benefit due to its high content of pertussis toxoid.
-
We are proud to be "2018 Distributor of the year"
Standing out from keen competitions, we are very proud to announce that we were the winner of the “2018 Distributor of the Year” award at AJ Vaccines Summit last week.
-
Sveriges ambassadör Annika Thunborg deltog på VASE konferensen i Mexiko City
Ambassadören presenterade under mötet Sveriges aktiva roll inom Global Hälsa, vilken avgörande roll nya vacciner inom diarréområdet kan spela generellt och hur vacciner även kan minska det överhängande globala hotet från antibiotikaresistens.
-
Sweden's ambassador Annika Thunborg attended the VASE conference in Mexico City
During VASE 2018 the Ambassador presented Sweden's strategy in Global Health, the essential and lifesaving role new vaccines play in the field of diarrhoeal disease and how vaccines can reduce the imminent global threat of antibiotic resistance.
-
Nya kliniska ETVAX®-data presenteras vid VASE-konferens i Mexiko
Den 12–14 juni arrangeras International Vaccines Against Shigella and ETEC (VASE) i Mexiko City. Under mötet samlas världsledande forskare tillsammans med centrala beslutsfattare från WHO, Bill & Melinda Gates Foundation, PATH och ledande forskningsinstitut för att diskutera vacciner mot diarrésjukdomar orsakade av Shigella och ETEC. Vårt ETEC-vaccin, ETVAX®, är naturligtvis på agendan.
-
New ETVAX® data will be presented during Vaccines Against Shigella and ETEC (VASE) conference in Mexico
The International Vaccines Against Shigella and ETEC(VASE) Conference will be held on June 12 to 14, in Mexico City, Mexico. The aim of this collaborative, interactive gathering is to accelerate the development and introduction of vaccine to prevent and control diarrheal diseases. Our ETEC-vaccine, ETVAX®, is of course on the agenda when the global development of ETEC vaccines will be discussed
-
Kyoko Misawa joins Scandinavian Biopharma as Clinical study manager
Scandinavian Biopharma continues to expand and strengthen its organization. In April Kyoko Misawa started as Clinical Study Manager at Scandinavian Biopharma’s research subsidiary ETVAX AB. Kyoko has more than 20 years’ experience from the pharmaceutical and life science industry in both Japan and Sweden within the field of diabetes, antibiotic, inflammation and orphan drugs
Visa mer
Loading...